DOCSLIB.ORG

Hypercholesterolaemia and Its Management Deepak Bhatnagar,1,2 Handrean Soran,1 Paul N Durrington1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hypercholesterolaemia and Its Management Deepak Bhatnagar,1,2 Handrean Soran,1 Paul N Durrington1 For the full versions of these articles see bmj.com CLINICAL REVIEW Hypercholesterolaemia and its management Deepak Bhatnagar,1,2 Handrean Soran,1 Paul N Durrington1 PRACTICE,pp509,510 Hypercholesterolaemia is one of the major causes of the optimal levels of plasma cholesterol should be atherosclerosis. Although there are many causes, ≤4 mmol/l (LDL cholesterol ≤2 mmol/l) in patients 1University of Manchester hypercholesterolaemia is the permissive factor that with pre-existing atherosclerotic disease or diabetes or Cardiovascular Research Group, allows other risk factors to operate.1 The incidence of in those who have a combination of other risk factors Core Technology Facility, Manchester M13 9NT coronary heart disease is usually low where population that produce a risk of cardiovascular disease (coronary 2 2Diabetes Centre, Royal Oldham plasma cholesterol concentrations are low. In Britain heart disease and stroke) of 20% or more over the next Hospital, Oldham OL1 2JH coronary heart disease is a major cause of mortality, 10 years.8 Theseriskfactorsincludemalesex, Correspondence to: D Bhatnagar, and a recent Department of Health survey suggested increased age, cigarette smoking, high blood pressure, Diabetes Centre, Royal Oldham that the average plasma cholesterol concentration in Hospital, Oldham OL1 2JH impaired fasting glucose concentration, low concen- [email protected] the United Kingdom was 5.9 mmol/l, much higher trations of high density lipoprotein (HDL) cholesterol, than the 4 mmol/l seen in rural China and Japan, where raised triglycerides, Indian subcontinent ancestry, and Cite this as: BMJ 2008;337:a993 3 doi:10.1136/bmj.a993 heart disease is uncommon. Many studies before and low socioeconomic class. after the introduction of statins have indicated that reducingthe prevalence of hypercholesterolaemia is an Who gets hyperlipidaemia? important means of decreasing coronary risk. Hypercholesterolaemia usually results from nutri- tional factors such as obesity and a diet high in What is hypercholesterolaemia? saturated fats combined with an underlying polygenic Cholesterol plays an important role as the precursor for predisposition. There is overproduction of LDL,9 and steroid hormones and bile acids and it is essential for the structural integrity of cell membranes. It is transported in the body in lipoproteins. Figure 1 Box 1 Causes of hyperlipidaemia shows the role of cholesterol in lipoprotein meta- Some causes of secondary hyperlipidaemia bolism. Conventionally the upper limit for laboratory Nephrotic syndrome reference ranges is based on the 95th or 90th centile Obstructive jaundice for a healthy population. This does not apply to plasma Hypothyroidism cholesterol, however, as several studies show that the Cushing’ssyndrome epidemiological relation between plasma cholesterol Anorexia nervosa and risk of coronary heart disease extends to the lower end of the cholesterol distribution. Although the Thiazide diuretics SOURCES AND relation becomes progressively steeper, there is no Ciclosporin SELECTION CRITERIA obvious threshold below which it ceases to exist.5 Some causes of mixed hyperlipidaemia* We selected references if Therefore, it is more rational to base a desirable or Type 2 diabetes mellitus they included a recent healthy concentration of plasma cholesterol on the Obesity, particularly if accompanied by features of the meta-analysis or value at which coronary risk is considered unaccep- metabolic syndrome provided a useful, tably high. Most patients developing coronary heart Alcohol excess objective, and disease have plasma cholesterol concentrations that are comprehensive account likely to be between the 30th and 90th centile for their Monoclonal gammopathy including extensive population of origin.6 A population is considered to be Renal dialysis recent references. We unhealthy when its average plasma cholesterol con- Glucocorticoids chosethemfroma centration exceeds 5 mmol/l (equivalent to low density β search of PubMed, blockers lipoprotein (LDL) cholesterol of 3 mmol/l).7 personal reference lists, Retinoic acid derivatives The Joint British Societies (JBS2) guidelines on and three textbooks26-28 *Increase in plasma cholesterol and triglycerides prevention of cardiovascular disease recommend that BMJ | 30 AUGUST 2008 | VOLUME 337 503 CLINICAL REVIEW its genetic component is unlikely to be monogenic, unless it is extreme. Hypercholesterolaemia can also Box2CalculatingLDLcholesterolandnon-HDLcholesterol concentrations* have an entirely genetic cause. A common example of = this is monogenic familial hypercholesterolaemia, an Low density lipoprotein cholesterol total serum cholesterol − (HDL cholesterol + (serum triglycerides/ autosomal dominant disorder in which the LDL 2.2)) cholesterol is raised from birth (table 1). 10 It is = − characterised by a dominant pattern of inheritance of Non-HDL cholesterol total cholesterol HDL cholesterol premature coronary disease and/or tendon *All values in mmol/l xanthomata. 11 Raised plasma triglyceride concentration in associa- tion with hypercholesterolaemia is common (table 2) pancreatitis may occur. Such patients should be and poses an additional risk of coronary heart referred to lipid clinics for treatment. disease. 12 Usually such patients have an increase in Remnant removal disease (type III hyperlipopro- both low density lipoprotein (VLDL) cholesterol and teinaemia) leads to combined hyperlipidaemia.14 LDL cholesterol and a decrease in HDL cholesterol. Although rare, it carries a high risk of both coronary This condition is called combined hyperlipidaemia or, heart disease and peripheral vascular disease early in if there is a strong familial tendency, familial combined life. Typically striate palmar and tuberoeruptive hyperlipidaemia. Usually the disorder is polygenic xanthomata occur.15 Chylomicron remnants accumu- with a strong overlap with glucose intolerance, late in the circulation owing to homozygosity for the diabetes, and the metabolic syndrome and may apo E2 isoform of apolipoprotein E, the ligand precede the onset of diabetes. 13 important for their hepatic clearance. It has variable Occasionally patients with hypercholesterolaemia penetrance, suggesting that some other cause such as have a plasma triglyceride concentration of >10 mmol/ obesity or insulin resistance is necessary for its l owing to an increasein both chylomicrons and VLDL. expression. The plasma has a milky appearance and eruptive xanthomata, and other features such as acute Table 2 and box 1 outline the diagnostic classifica- tion of hypercholesterolaemia. Before primary hypercholesterolaemia is diagnosed underlying sec- ondary causes should be excluded. Dietary cholesterol absorbed in the How to investigate the patient with gut is transported to the liver in chylomicrons, which are rich in hypercholesterolaemia triglyceride. Cholesterol is also Before treatment is started for hypercholesterolaemia a Gut Apo A1 synthesised de novo in the liver, gut, detailed history, clinical examination, and baseline Chylomicron and central nervous system. Apo B48 Cholesterol in the liver is packaged laboratory tests are needed to discover causes of along with triglycerides and secreted secondary hypercholesterolaemia, manifestations of TG as VLDL, which is then converted into LDL in the circulation. LDL delivers primary lipoprotein disorders, and any complications TG cholesterol to most tissues, and the related to atherosclerosis. A family and occupational Lipoprotein uptake of cholesterol is facilitated by — lipase TG LDL receptors. Excess cholesterol is history including a history of smoking, alcohol TG removed from cells by HDL and is intake, and dietary preferences—will help to indicate then either transferred to LDL and TG VLDL, whence it can return to the the extent to which these factors contribute to Apo A1 LRP liver via hepatic LDL receptors or be hypercholesterolaemia and/or to risk of cardiovascular ABC A1 Liver taken up directly from HDL via the Un ’ es disease and to gauge the patient s ability to change C te hepatic class B scavenger receptors. ho rif le ied LDL SR B1 C st Cholesterol is also excreted in bile lifestyle. The physical examination should include ho ero les l HDL receptor tero both as free cholesterol and as bile es l blood pressure, body weight, height, waist circumfer- ter acids, which are both subject to er enterohepatic circulation. Most of the ence, and a search for xanthomata. A family history is yl est plasma cholesterol is present in LDL, essential to facilitate cascade testing in primary with smaller amounts in VLDL and Apo B100 CholesterCETP 16 VLDL HDL. Total plasma cholesterol mainly hypercholesterolaemia. Reverse reflects LDL cholesterol. In the fasting TG cholesterol state, plasma triglyceride generally Laboratory assessment in hypercholesterolaemia Lipoprotein transport indicates the VLDL concentration. lipase TG IDL When screening for hypercholesterolaemia it is Tissue fluid LDL = low density lipoprotein advisable to take blood samples after a fast of at least TG LDL HDL = high density lipoprotein VLDL = very low density lipoprotein 10 hours to avoid the postprandial contribution to IDL = intermediate density lipoprotein plasma triglycerides. If plasma triglycerides do not Arterial wall LDL CETP = cholesteryl ester transfer protein receptor ABCAI = ATP binding cassette transporter 1 exceed 4.5 mmol/l, the LDL cholesterol concentration Modified LDL SRB 1 = class B scavenger receptors Foam LRP = lipoprotein related receptor can be calculated
Load more

Recommended publications
  • Chapter 7: Monogenic Forms of Diabetes
    CHAPTER 7 MONOGENIC FORMS OF DIABETES Mark A. Sperling, MD, and Abhimanyu Garg, MD Dr. Mark A. Sperling is Emeritus Professor and Chair, University of Pittsburgh, Department of Pediatrics, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA. Dr. Abhimanyu Garg is Professor of Internal Medicine and Chief of the Division of Nutrition and Metabolic Diseases at University of Texas Southwestern Medical Center, Dallas, TX. SUMMARY Types 1 and 2 diabetes have multiple and complex genetic influences that interact with environmental triggers, such as viral infections or nutritional excesses, to result in their respective phenotypes: young, lean, and insulin-dependence for type 1 diabetes patients or older, overweight, and often manageable by lifestyle interventions and oral medications for type 2 diabetes patients. A small subset of patients, comprising ~2%–3% of all those diagnosed with diabetes, may have characteristics of either type 1 or type 2 diabetes but have single gene defects that interfere with insulin production, secretion, or action, resulting in clinical diabetes. These types of diabetes are known as MODY, originally defined as maturity-onset diabetes of youth, and severe early-onset forms, such as neonatal diabetes mellitus (NDM). Defects in genes involved in adipocyte development, differentiation, and death pathways cause lipodystrophy syndromes, which are also associated with insulin resistance and diabetes. Although these syndromes are considered rare, more awareness of these disorders and increased availability of genetic testing in clinical and research laboratories, as well as growing use of next generation, whole genome, or exome sequencing for clinically challenging phenotypes, are resulting in increased recognition. A correct diagnosis of MODY, NDM, or lipodystrophy syndromes has profound implications for treatment, genetic counseling, and prognosis.
    [Show full text]
  • An Educational Booklet for Patients with Familial Hypercholesterolemia
    Illustrations > Jean Lambert Illustrations graphic design > www.mine-de-rien.net graphic Chol/29/P030/01-01/10 NLA An educational booklet for patients with familial hypercholesterolemia This brochure was provided by Genzyme Corporation for use by the Foundation of the National Lipid Association. DR. LEIV OSE www.learnyourlipids.com CONTENTS PART 1 What will you learn from this booklet? 02 FAMILIAL HYPERCHOLESTEROLEMIA PART 1: FAMILIAL HYPERCHOLESTEROLEMIA 03 1 - What is Familial Hypercholesterolemia? 03 WHAT WILL YOU 2 - What is LDL-Cholesterol? 04 3 - What are the causes of FH? 05 LEARN FROM THIS GREAT GRANDMOTHER GREAT GRANDFATHER 4 - When should FH be suspected? 07 FH NON FH BOOKLET? 5 - How is FH diagnosed? 09 6 - How early can FH be diagnosed? 09 Woman You will learn about Familial PART 2: TREATMENT 10 GRANDMOTHER GRANDFATHER Hypercholesterolemia, NON FH FH Woman with FH 1 - How can LDL-Cholesterol be reduced? 10 its cause, and the potential 2 - Step 1: Dietary management of FH 11 Man consequences of this a) How does diet affect LDL-Cholesterol? 11 disease. You will learn b) What sort of diet? 11 Man with FH about high cholesterol 3 - Step 2: Using medication 12 AUNT MOTHER FATHER UNCLE and what this might mean a) How does medication affect LDL-Cholesterol? 12 NON FH FH NON FH FH for your heart and blood b) Which drug treatments reduce LDL-Cholesterol and how? 13 FIGURE 1: 4 - Why is lifelong treatment important? vessels. Most importantly 15 FH is an inherited disease, you will learn how to find PART 3: CARDIOVASCULAR DISEASE AND LIPOPROTEINS 16 which can usually be traced out whether someone in 1 - What is cardiovascular disease? 16 DAUGTER SON over several generations.
    [Show full text]
  • High Burden of Recurrent Cardiovascular Events
    High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry Sophie Béliard, Franck Boccara, Bertrand Cariou, Alain Carrié, Xavier Collet, Michel Farnier, Jean Ferrières, Michael Krempf, Noël Peretti, Jean Pierre Rabès, et al. To cite this version: Sophie Béliard, Franck Boccara, Bertrand Cariou, Alain Carrié, Xavier Collet, et al.. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry. Atherosclerosis, Elsevier, 2018, 277, pp.334-340. 10.1016/j.atherosclerosis.2018.08.010. hal-01996274 HAL Id: hal-01996274 https://hal-amu.archives-ouvertes.fr/hal-01996274 Submitted on 1 Feb 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License Elsevier Editorial System(tm) for Atherosclerosis Manuscript Draft Manuscript Number: ATH-D-18-00445R1 Title: High burden of recurrent cardiovascular events in heterozygous familial
    [Show full text]
  • Lipodystrophy Due to Adipose Tissue Specific Insulin Receptor
    Page 1 of 50 Diabetes Lipodystrophy Due to Adipose Tissue Specific Insulin Receptor Knockout Results in Progressive NAFLD Samir Softic1,2,#, Jeremie Boucher1,3,#, Marie H. Solheim1,4, Shiho Fujisaka1, Max-Felix Haering1, Erica P. Homan1, Jonathon Winnay1, Antonio R. Perez-Atayde5, and C. Ronald Kahn1. 1 Section on Integrative Physiology and Metabolism, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 2 Division of Gastroenterology, Hepatology and Nutrition, Boston Children’s Hospital, Boston, MA 3 Cardiovascular and Metabolic Diseases iMed, AstraZeneca R&D, 431 83 Mölndal, Sweden (current address) 4 KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway 5 Department of Pathology, Boston Children’s Hospital, and Harvard Medical School, Boston, MA # These authors contributed equally to this work. Corresponding author: C. Ronald Kahn, MD Joslin Diabetes Center One Joslin Place Boston, MA 02215 Phone: (617)732-2635 Fax:(617)732-2487 E-mail: [email protected] Keywords: Insulin receptors, IGF-1 receptors, lipodystrophy, diabetes, dyslipidemia, fatty liver, liver tumor, NAFLD, NASH. Running title: Lipodystrophic mice develop progressive NAFLD 1 Diabetes Publish Ahead of Print, published online May 10, 2016 Diabetes Page 2 of 50 SUMMARY Ectopic lipid accumulation in the liver is an almost universal feature of human and rodent models of generalized lipodystrophy and also is a common feature of type 2 diabetes, obesity and metabolic syndrome. Here we explore the progression of fatty liver disease using a mouse model of lipodystrophy created by a fat-specific knockout of the insulin receptor (F-IRKO) or both IR and insulin-like growth factor-1 receptor (F- IR/IGF1RKO).
    [Show full text]
  • Reducing the Burden of Disease and Death from Familial Hypercholesterolemia: a Call to Action Joshua W
    Editorial Reducing the burden of disease and death from familial hypercholesterolemia: A call to action Joshua W. Knowles, MD, PhD, a,b Emily C. O’Brien, PhD, c Karen Greendale, MA, CGC, b Katherine Wilemon, BS, b Jacques Genest, MD, d Laurence S. Sperling, MD, e William A. Neal, MD, f Daniel J. Rader, MD, g and Muin J. Khoury, MD, PhD h Stanford, South Pasadena, CA; Durham, NC; Montreal, Canada; Atlanta, GA; Morgantown, WV; and Philadelphia, PA Familial hypercholesterolemia (FH) is a genetic disease characterized by substantial elevations of low-density lipoprotein cholesterol, unrelated to diet or lifestyle. Untreated FH patients have 20 times the risk of developing coronary artery disease, compared with the general population. Estimates indicate that as many as 1 in 500 people of all ethnicities and 1 in 250 people of Northern European descent may have FH; nevertheless, the condition remains largely undiagnosed. In the United States alone, perhaps as little as 1% of FH patients have been diagnosed. Consequently, there are potentially millions of children and adults worldwide who are unaware that they have a life-threatening condition. In countries like the Netherlands, the United Kingdom, and Spain, cascade screening programs have led to dramatic improvements in FH case identification. Given that there are currently no systematic approaches in the United States to identify FH patients or affected relatives, the patient-centric nonprofit FH Foundation convened a national FH Summit in 2013, where participants issued a “call to action” to health care providers, professional organizations, public health programs, patient advocacy groups, and FH experts, in order to bring greater attention to this potentially deadly, but (with proper diagnosis) eminently treatable, condition.
    [Show full text]
  • Commonly Used Lipidcentric ICD-10 (ICD-9) Codes
    Commonly Used Lipidcentric ICD-10 (ICD-9) Codes *This is not an all inclusive list of ICD-10 codes R.LaForge 11/2015 E78.0 (272.0) Pure hypercholesterolemia E78.3 (272.3) Hyperchylomicronemia (Group A) (Group D) Familial hypercholesterolemia Grütz syndrome Fredrickson Type IIa Chylomicronemia (fasting) (with hyperlipoproteinemia hyperprebetalipoproteinemia) Hyperbetalipoproteinemia Fredrickson type I or V Hyperlipidemia, Group A hyperlipoproteinemia Low-density-lipoid-type [LDL] Lipemia hyperlipoproteinemia Mixed hyperglyceridemia E78.4 (272.4) Other hyperlipidemia E78.1 (272.1) Pure hyperglyceridemia Type 1 Diabetes Mellitus (DM) with (Group B) hyperlipidemia Elevated fasting triglycerides Type 1 DM w diabetic hyperlipidemia Endogenous hyperglyceridemia Familial hyperalphalipoproteinemia Fredrickson Type IV Hyperalphalipoproteinemia, familial hyperlipoproteinemia Hyperlipidemia due to type 1 DM Hyperlipidemia, Group B Hyperprebetalipoproteinemia Hypertriglyceridemia, essential E78.5 (272.5) Hyperlipidemia, unspecified Very-low-density-lipoid-type [VLDL] Complex dyslipidemia hyperlipoproteinemia Elevated fasting lipid profile Elevated lipid profile fasting Hyperlipidemia E78.2 (272.2) Mixed hyperlipidemia (Group C) Hyperlipidemia (high blood fats) Broad- or floating-betalipoproteinemia Hyperlipidemia due to steroid Combined hyperlipidemia NOS Hyperlipidemia due to type 2 diabetes Elevated cholesterol with elevated mellitus triglycerides NEC Fredrickson Type IIb or III hyperlipoproteinemia with E78.6 (272.6)
    [Show full text]
  • Phenotypic and Clinical Outcome Studies in Amyloidosis and Associated Autoinflammatory Diseases
    Phenotypic and clinical outcome studies in amyloidosis and associated autoinflammatory diseases Taryn Alessandra Beth Youngstein Doctor of Medicine 2019 University College London UK National Amyloidosis Centre Centre for Acute Phase Protein Research Department of Medicine Royal Free Hospital Rowland Hill Street London NW3 2PF MD(Res)Thesis 1 Declaration I, Taryn Alessandra Beth Youngstein, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, it has been declared within the thesis. 2 Abstract Background: Systemic Amyloidosis results from the deposition of insoluble proteins as amyloid that disrupt organ function with time. Over 30 proteins are known to form amyloid and the identification of the precursor protein is essential as it guides treatment strategies. In AA amyloidosis, the precursor protein is Serum Amyloid A (SAA) which forms amyloid when raised in the blood over time. Thus, AA amyloidosis is a feared complication of the hereditary periodic fever syndromes and other autoinflammatory diseases. Aims: 1. To investigate transthyretin (TTR) amyloid and describe non-cardiac TTR deposition 2. To determine the role of carpal tunnel biopsy in diagnosis of TTR amyloid 3. Investigate and define the changing aetiology of AA amyloidosis 4. To investigate the safety of IL-1 antagonism for autoinflammatory disease in pregnancy 5. Delphi consensus study to define phenotype and management approaches in the autoinflammatory disease Deficiency of ADA2 (DADA2). Results and Conclusions 1. Non-cardiac TTR deposits were identified in 25 biopsies from the tissues of the bladder, duodenum, bone marrow, carpal tunnel tenosynovium, colon, stomach, lung, prostate, muscle. 84% had concurrent evidence of cardiac amyloid and 64% fulfilled consensus criteria for cardiac amyloidosis at presentation.
    [Show full text]
  • Ldl Familial Hypercholesterolemia
    WHAT IS FAMILIAL HYPERCHOLESTEROLEMIA (FH)? FH is a common condition in which the body is unable to process its natural supply of cholesterol. This inherited illness is due to one or, more rarely, two abnormal chromosomes, which make the liver ineffective at transporting cholesterol in the body. High levels of “bad” cholesterol (low-density lipoprotein-cholesterol or LDL-C) can block arteries and lead to a heart attack or stroke if left untreated.1 THINGS YOU NEED TO KNOW ABOUT FAMILIAL HYPERCHOLESTEROLEMIA WHO IS AFFECTED? IS CHOLESTEROL BAD? FH affects an estimatedone in 300 to one Not in itself, but too much of it can be dangerous for your 2 health. Cholesterol plays an important role in the body as it . in 500 people worldwide helps make the outer coating of cells; is necessary for bile acids that help digest food; and allows the body to make Up to 80% of affected people Vitamin D and hormones. HDL (high-density lipoproteins) in most countries and LDL move cholesterol to the parts of your body that remain undiagnosed need it, however, too much LDL in your bloodstream leads throughout the world.2 to excess cholesterol being deposited in your arteries, which can cause plaques and lead to heart disease.1 If left untreated: • the risk of developing early heart disease is 3 20 times greater than in the general population; • men have a 50% risk for a coronary event by the age of 50; 4 women a 30% risk by the age of 60. LDL cholesterol LIVING WITH FH CAN FH BE TREATED? Yes, there are several types of treatments including CLICK ON PHOTO TO “statins”, cholesterol absorption inhibitors, bile acid ACCESS VIDEO sequestrants and PCSK9 inhibitors.
    [Show full text]
  • A Case Report of a Chinese Familial Partial Lipodystrophic Patient with Lamin A/C Gene R482Q Mutation and Polycystic Ovary Syndr
    s Case Re te po e r b t Su et al., Diabetes Case Rep 2017,2:1 s ia D Diabetes Case Reports DOI: 10.4172/2572-5629.1000117 ISSN: 2572-5629 ResearchCase Report Article Open Access A Case Report of a Chinese Familial Partial Lipodystrophic Patient with Lamin A/C Gene R482Q Mutation and Polycystic Ovary Syndrome Benli Su1*, Nan Liu1, Jia Liu2, Wei Sun1, Xia Zhang1 and Ping Zhang1 1Department of Endocrinology and Metabolism, The Second Hospital of Dalian Medical University, Dalian 116027, China 2Department of Endocrinology and Metabolism, Dalian Fifth Hospital, Dalian 116023, China Abstract Individuals with Familial partial lipodystrophy (FPLD), Dunnigan variety is a rare autosomal dominant disorder caused by missense mutations in Lamin gene are predisposed to insulin resistance and its complications including features of polycystic ovarian syndrome. We present a single case report about a 26-year-old Chinese woman consulted for infertility. On physical examination acanthosis nigricans and central distribution of fat were found. Her masculine type morphology, muscular appearance of the limbs and excess fat deposits in the face and neck promote us to suspect the existence of partial lipodystrophy. Biochemistry testing confirmed glucose intolerance associated with a severe insulin resistance, hypertriglyceridemia, and polycystic ovary syndrome. The detection of a heterozygous missense mutation in LAMIN A/C gene at position 482 confirmed the diagnosis of FPLD2. In conclusion, characteristic features of FPLD and mutation screening allow early diagnosis of this disorder, and facilitate appropriate clinical treatment. Keywords: Familial partial lipodystrophy; Lamin; Polycystic ovary but not spontaneous regular menses, and she received combined syndrome; Metabolism cyproterone acetate treatment that induced cyclical withdrawal bleeding, but oligomenorrhea recurred after interruption of this Introduction treatment.
    [Show full text]
  • Familial Partial Lipodystrophy
    Familial Partial Lipodystrophy Purvisha Patel; Ralph Starkey, MD; Michele Maroon, MD The lipodystrophies are rare disorders character- ized by insulin resistance and the absence or loss of body fat. The 4 subtypes of lipodystrophy are characterized by onset and distribution. Partial lipodystrophy is rare, with loss of fat from the extremities and excess fat accumulation in the face and neck; recognizing this phenotype and subsequent referral for endocrinologic care may improve outcome and reduce mortality. ipodystrophies are rare disorders characterized by insulin resistance and the absence or L loss of body fat.1 Classification of the 4 main subtypes of lipodystrophy is based on onset (congenital/familial vs acquired/sporadic) and dis- Figure not available online tribution (total/generalized vs partial). Congenital total lipodystrophy (also known as Berardinelli syndrome, Seip syndrome) is a rare autosomal- recessive disorder marked by an almost complete lack of adipose tissue from birth. Familial partial lipodystrophy (also known as Kobberling-Dunnigan syndrome) involves loss of subcutaneous fat from the extremities and accumulation of excess fat in the face and neck and to a lesser extent in the hands and feet. Acquired total lipodystrophy (also known as lipoatrophy, Lawrence-Seip syndrome) presents with generalized loss of fat beginning in childhood. Acquired partial lipodystrophy (also known as progressive lipodystrophy, partial lipoat- Figure 1. Accentuation of fat pads in the face and neck. rophy, Barraquer-Simons syndrome) is character- ized by loss of fat only from the upper extremities, face, and trunk.2 tional uterine bleeding (gravida 2, para 1, AB 1) Case Report necessitating total hysterectomy. On physical A 39-year-old white woman presented with the examination, accentuation of fat pads in the face complaint of thickened brown skin on the neck and and neck (Figure 1), central obesity, and prominent medial thighs.
    [Show full text]
  • Familial Hypercholesterolemia in Premature Acute Coronary Syndrome
    Journal of Clinical Medicine Article Familial Hypercholesterolemia in Premature Acute Coronary Syndrome. Insights from CholeSTEMI Registry Rebeca Lorca 1,2,3, Andrea Aparicio 2, Elias Cuesta-Llavona 1,3, Isaac Pascual 2,3,* , Alejandro Junco 2 , Sergio Hevia 2, Francisco Villazón 4, Daniel Hernandez-Vaquero 2,3 , 1,2,3 1,2,3 1,3 1,3, Jose Julian Rodríguez Reguero , Cesar Moris , Eliecer Coto , Juan Gómez y and 2,3, Pablo Avanzas y 1 Reference Unit of Familiar Cardiomyopathies-HUCA, Área del Corazón y Departamento de Genética Molecular, Hospital Universitario Central Asturias, 33014 Oviedo, Spain; [email protected] (R.L.); [email protected] (E.C.-L.); [email protected] (J.J.R.R.); [email protected] (C.M.); [email protected] (E.C.); [email protected] (J.G.) 2 Heart Area, Hospital Universitario Central de Asturias, 33014 Oviedo, Spain; [email protected] (A.A.); [email protected] (A.J.); [email protected] (S.H.); [email protected] (D.H.-V.); [email protected] (P.A.) 3 Instituto de Investigación Sanitaria del Principado de Asturias, ISPA, 33014 Oviedo, Spain 4 Endocrinology Department, Hospital Universitario Central Asturias, 33014 Oviedo, Spain; [email protected] * Correspondence: [email protected] Equal contribution of two last co-authors: Pablo Avanzas and Juan Gómez. y Received: 3 September 2020; Accepted: 26 October 2020; Published: 29 October 2020 Abstract: Familial hypercholesterolemia (FH) is an underdiagnosed genetic inherited condition that may lead to premature coronary artery disease (CAD). FH has an estimated prevalence in the general population of about 1:313. However, its prevalence in patients with premature STEMI (ST-elevation myocardial infarction) has not been widely studied.
    [Show full text]
  • Familial Hypercholesterolemia
    Familial hypercholesterolemia Description Familial hypercholesterolemia is an inherited condition characterized by very high levels of cholesterol in the blood. Cholesterol is a waxy, fat-like substance that is produced in the body and obtained from foods that come from animals (particularly egg yolks, meat, poultry, fish, and dairy products). The body needs this substance to build cell membranes, make certain hormones, and produce compounds that aid in fat digestion. In people with familial hypercholesterolemia, the body is unable to get rid of extra cholesterol, and it builds up in the blood. Too much cholesterol increases a person's risk of developing heart disease. People with familial hypercholesterolemia have a high risk of developing a form of heart disease called coronary artery disease at a young age. This condition occurs when excess cholesterol in the bloodstream is deposited on the inner walls of blood vessels, particularly the arteries that supply blood to the heart (coronary arteries). The abnormal buildup of cholesterol forms clumps (plaques) that narrow and harden artery walls. As the plaques get bigger, they can clog the arteries and restrict the flow of blood to the heart. The buildup of plaques in coronary arteries causes a form of chest pain called angina and greatly increases a person's risk of having a heart attack. Familial hypercholesterolemia can also cause health problems related to the buildup of excess cholesterol in tissues other than the heart and blood vessels. If cholesterol accumulates in the tissues that attach muscles to bones (tendons), it causes characteristic growths called tendon xanthomas. These growths most often affect the Achilles tendons, which attach the calf muscles to the heels, and tendons in the hands and fingers.
    [Show full text]